Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 1/20 | 0.56 |
| ▸ | KDM4A | O75164 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | NQO2 | P16083 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26659635 | 0.98 | KCNA5 (0.55) | KCNA5KDM4AHTTCA12CA1 | |
| Water SCHEMBL30667520 | 0.96 | KCNA5 (0.53) | KCNA5KDM4AHTTCA12CA1 | |
| SCHEMBL498661 | 0.89 | KCNA5 (0.67) | KCNA5KDM4AHTTCA12CA1 | |
| SCHEMBL25762436 | 0.88 | KCNA5 (0.56) | KCNA5KDM4AHTTCA12CA1 | |
| SCHEMBL30159605 | 0.87 | KCNA5 (0.56) | KCNA5KDM4ACA12CA1CA7 | |
| SCHEMBL8018113 | 0.87 | KCNA5 (0.56) | KCNA5KDM4ACA12CA1CA7 | |
| SCHEMBL6290025 | 0.87 | KCNA5 (0.50) | KCNA5KDM4AHTTCA12CA1 | |
| SCHEMBL28255694 | 0.87 | KCNA5 (0.50) | KCNA5KDM4AHTTCA12CA1 | |
| SCHEMBL1965799 | 0.87 | KCNA5 (0.50) | KCNA5KDM4AHTTCA12CA1 | |
| SCHEMBL2158784 | 0.87 | KCNA5 (0.55) | KCNA5KDM4ACA12CA1CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570655-B2 | Cysteine covalent modifiers of AKT1 and uses thereof | TERREMOTO BIOSCIENCES, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20260027131-A1 | PRODRUGS, PRODRUG COMPOSITIONS AND RELATED METHODS | PRAESIDIA BIOTHERAPEUTICS INC (US) | 2026-01-29 | — | — | US | disclosed |
| WO-2025081045-A9 | CYSTEINE COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. (US) | 2025-12-26 | — | — | WO | disclosed |
| WO-2025217330-A1 | CYSTEINE COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. (US) | 2025-10-16 | — | — | WO | disclosed |
| US-20250289819-A1 | CYSTEINE COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. | 2025-09-18 | — | — | US | disclosed |
| WO-2025081045-A1 | CYSTEINE COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. (US) | 2025-04-17 | — | — | WO | disclosed |
| US-20250018046-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS | BIOGEN MA INC. | 2025-01-16 | — | — | US | disclosed |
| US-20240327334-A1 | Covalent Inhibitors As Antiviral Agents | ENANTA PHARMACEUTICALS, INC. | 2024-10-03 | — | — | US | disclosed |
| CN-118302414-A | Oxazole, oxadiazole and indole derivatives useful for inhibiting USP28 | 卡莫特医疗有限公司 | 2024-07-05 | — | — | CN | disclosed |
| WO-2024137764-A1 | NOVEL COVALENT INHIBITORS AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-1998005627-A1 | BORONIC COMPOUND COMPLEXING REAGENTS AND HIGHLY STABLE COMPLEXES | PROLINX, INC. (US) | 1998-02-12 | — | — | WO | disclosed |
| EP-0672034-A4 | BENZIMIDAZOLE COMPOUNDS WHICH INHIBIT PLATELET AGGREGATION. | SMITHKLINE BEECHAM CORP (US) | 1996-09-25 | — | — | EP | disclosed |
| EP-0692982-A1 | RADIOLABELED PLATELET GPIIb/IIIa RECEPTOR ANTAGONISTS AS IMAGING AGENTS FOR THE DIAGNOSIS OF THROMBOEMBOLIC DISORDERS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-01-24 | — | — | EP | disclosed |
| EP-0672034-A1 | BENZIMIDAZOLE COMPOUNDS WHICH INHIBIT PLATELET AGGREGATION | SMITHKLINE BEECHAM CORPORATION (US) | 1995-09-20 | — | — | EP | disclosed |
| US-5387671-A | Antiinflammatory agents | ABBOTT LABORATORIES (US) | 1995-02-07 | — | — | US | disclosed |
| EP-0564533-A4 | MODIFIED HEXA- AND HEPTAPEPTIDE ANAPHYLATOXIN RECEPTOR LIGANDS | ABBOTT LAB (US) | 1994-11-02 | — | — | EP | disclosed |
| WO-1994022494-A1 | RADIOLABELED PLATELET GPIIb/IIIa RECEPTOR ANTAGONISTS AS IMAGING AGENTS FOR THE DIAGNOSIS OF THROMBOEMBOLIC DISORDERS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-10-13 | — | — | WO | disclosed |
| WO-1994012478-A1 | BENZIMIDAZOLE COMPOUNDS WHICH INHIBIT PLATELET AGGREGATION | SMITHKLINE BEECHAM CORPORATION (US) | 1994-06-09 | — | — | WO | disclosed |
| EP-0564533-A1 | MODIFIED PENTA- AND HEXAPEPTIDE ANAPHYLATOXIN RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 1993-10-13 | — | — | EP | disclosed |
| WO-1992012168-A1 | MODIFIED HEXA- AND HEPTAPEPTIDE ANAPHYLATOXIN RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 1992-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250018046-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS | IRAK4, IRAK2, IRAK1 | KCNA5 4554/4885KDM4A 213/4885HTT 3198/4885 |
| US-20260027131-A1 | PRODRUGS, PRODRUG COMPOSITIONS AND RELATED METHODS | DNPEP, SLC7A1, SLC6A7 | KCNA5 2811/4885KDM4A 1671/4885HTT 3291/4885 |
| US-12570655-B2 | Cysteine covalent modifiers of AKT1 and uses thereof | AKT1, AKT2, AKT3 | KCNA5 3725/4885KDM4A 3980/4885HTT 3562/4885 |
| US-20240327334-A1 | Covalent Inhibitors As Antiviral Agents | SARS1, ACE, ACE2 | KCNA5 4193/4885KDM4A 356/4885HTT 3688/4885 |
| US-20250289819-A1 | CYSTEINE COVALENT MODIFIERS OF AKT1 AND USES THEREOF | AKT1, AKT2, AKT3 | KCNA5 4572/4885KDM4A 2925/4885HTT 2987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.